In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X and Sanofi begin joint research on AI-driven drug development
BioMed X and Sanofi begin joint research on AI-driven drug development
Pharmaceutical Technology
This latest effort is yet another AI play from BioMed X, hoping to capitalise on a rapidly growing market.
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Yahoo! Finance
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations…
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Newswire
The “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE) team joins eight other active research teams at the BioMed X Institute in Germany, and it is one of four new projects launched by BioMed X in 2023. To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.
Visit: Das BioMed X Institute startet sein erstes Forschungsprojekt mit Sanofi zur Anwendung von künstlicher Intelligenz in der Arzneimittelentwicklung
Das BioMed X Institute startet sein erstes Forschungsprojekt mit Sanofi zur Anwendung von künstlicher Intelligenz in der Arzneimittelentwicklung
Wallstreet Online
Ein neues BioMed X-Forschungsteam wird mit Unterstützung von Sanofi eine Computerplattform entwickeln, die die Entwicklung von Medikamenten beschleunigen soll.
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Bloomberg
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE).
Visit: BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
BioSpace
Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.
Visit: Inspiring, Exciting, Unforgettable: Fueling Innovation in Science
Inspiring, Exciting, Unforgettable: Fueling Innovation in Science
Chemistry Views
Even in case of a large chemical or pharmaceutical company, 99.99 % of all scientists work outside of the organization. So, as a company, how can you increase the percentage of scientists involved in generating new ideas? And how do you attract the best minds to participate?
Visit: Johnson & Johnson sucht Innovationen in Düsseldorf, Heidelberg und München
Johnson & Johnson sucht Innovationen in Düsseldorf, Heidelberg und München
Transkript
Das Innovationsteam von Johnson & Johnson in Europa hat in der vergangenen Woche den drei “führenden Ökosystemen der Biowissenschaften in Deutschland” (so die Eigendarstellung des Unternehmens) einen Besuch abgestattet. Man wollte sich persönlich in Düsseldorf, Heidelberg und München mit Unternehmern, Akademikern, Technologietransferbüros und anderen führenden Köpfen der Biowissenschaften treffen.
Visit: German company expansions reflect European country’s strong trade, business ties to CT
German company expansions reflect European country’s strong trade, business ties to CT
Hartford Business Journal
German biomedical institute BioMed X recently launched its first operation in New Haven, which will focus on immunology and tissue engineering research. BioMed will employ six researchers located near Yale University.
Visit: Five German Companies Announce Expansions in Connecticut
Five German Companies Announce Expansions in Connecticut
PR Newswire
AdvanceCT today announced that several German companies recently expanded their business or started expansion projects in Connecticut, including TRUMPF, BioMed X, Roehm, BYK North America and Eppendorf North America.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches New Global Call for Applications: Identification of Active Small Molecules for Drug Discovery
AION Labs, In Continued Partnership with BioMed X, Launches New Global Call for Applications: Identification of Active Small Molecules for Drug Discovery
Yahoo! Finance
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research and technology talent for new startup focused on: “AI-Powered Drug Discovery of New High-Affinity Small Molecules”.
Visit: AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery
AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery
Pharmaceutical Technology
The new startup will utilise cutting-edge methods to accelerate drug discovery research.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioSpace
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Wall Street Online
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Yahoo! Finance
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model launched today – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Access Wire
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on wound healing & fibrosis.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Open PR
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
PharmiWeb
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Access Wire
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Finanz Nachrichten
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of its new research project – “New Strategies to Enhance the Immunogenicity of Tumors” – in collaboration with Merck. The focus of this new research group will be to develop novel approaches for enhancing tumor immunogenicity to broaden the population of patients who could benefit from cancer immunotherapy.